Nouvelles Cliniques Nimoises
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The cardiology department at Nouvelles Cliniques Nimoises is advancing care for patients with valvular heart disease by studying optimal antithrombotic strategies after aortic bioprosthetic valve replacement, including the role of newer oral anticoagulants such as apixaban.
- Antithrombotic management post‑valve surgery
- Comparative effectiveness of anticoagulants versus aspirin
- Long‑term safety of bioprosthetic valve patients
These investigations aim to reduce thrombotic complications and improve survival for individuals receiving valve implants.
Digestive System Diseases
Research at the site focuses on moderate to severe ulcerative colitis, evaluating innovative induction therapies such as biologics and oral agents to achieve clinical remission.
- Biologic induction therapies for ulcerative colitis
- Oral small‑molecule treatments for active disease
- Safety and tolerability assessments in inflammatory bowel disease
The goal is to provide patients with more effective options that quickly control inflammation and improve quality of life.
Immune System Diseases
The clinic’s immune‑focused studies target immune‑mediated inflammation underlying conditions such as ulcerative colitis, exploring novel cytokine inhibitors and precision‑medicine approaches.
- Targeting cytokine pathways in chronic inflammation
- Development of next‑generation immunomodulators
- Personalized treatment strategies based on immune profiling
By refining therapeutic options, researchers aim to achieve durable remission with fewer side effects.
Immune System Phenomena
Investigations into immune system phenomena seek to understand the mechanisms that drive clinical remission and treatment response across multiple disease areas.
- Biomarker discovery for predicting therapeutic outcomes
- Mechanistic studies of immune modulation by new agents
- Evaluation of immune‑related safety signals in trials
This work supports the development of safer, more targeted therapies for patients with complex immune disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nouvelles Cliniques Nimoises
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF therapy | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Nov 2020 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 1 | Unknown | 2026-03-13 | 2026-03-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.